| Autor: |
Oleinik, L. A., Madonov, P. G., Pykhtina, M. B. |
| Předmět: |
|
| Zdroj: |
Molecular Biology; Apr2023, Vol. 57 Issue 2, p291-298, 8p |
| Abstrakt: |
This study provides an overview of scientific results on the feasibility of using type III interferons against SARS-CoV-2. We have analyzed data obtained from the PubMed electronic database for the period 2020‒2022. The results of our own studies of pharmacological substances based on recombinant IFN-λ1 and its pegylated form are also presented. Completed and ongoing investigations allow us to position IFN-λ as an effective therapeutic agent against SARS-CoV-2. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink